ISRG trades just 4% below its record high after a 32% surge over the past three months, driven by strong procedure growth, rising utilization, and early traction for the da Vinci 5 system.
ISRG stock has climbed nearly 40% from its October 2025 lows of approximately $425, currently trading near $590. What has spurred this remarkable rise?
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.
ISRG's single-port platform posts 91% procedure growth, led by Korea, with U.S. momentum building as new tools and indications expand adoption.
These healthcare growth stocks are profitable and revenue is growing at a double-digit pace. Intuitive Surgical is the top global player in the field of robotic surgery.
ISRG posts 20% Q3 procedure growth as da Vinci and Ion volumes accelerate, but investors question if product cycles and timing effects can sustain it.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $572.47, indicating a +1.88% shift from the previous trading day.
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical broadens its da Vinci SP system with FDA clearance for three new surgeries, expanding its role in minimally invasive care.
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $566.89, signifying a -1.47% move from its prior day's close.